Endothelial expression of MHC class II molecules in autoimmune disease

Current Pharmaceutical Design

Volumn 10, Issue 2, 2004, Pages 129-143

  Turesson, Carl ^a,b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b MAYO CLINIC   (United States)

Author keywords

Cardiovascular disease; Endothelial activation; Endothelial cells; HLA DQ; HLD DR; Major histocompatibility complex class II; Rheumatoid arthritis; T cells

Indexed keywords

ANTIOXIDANT; ATORVASTATIN; BETA INTERFERON; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; CYTOKINE; GAMMA INTERFERON; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PRAVASTATIN; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ALLOGRAFT; ANTIGEN EXPRESSION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CARDIOVASCULAR DISEASE; CELL ACTIVATION; CELL INTERACTION; CELLULAR IMMUNITY; CONGESTIVE CARDIOMYOPATHY; DRUG RESEARCH; ENDOTHELIUM CELL; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC TRANSCRIPTION; GRAFT REJECTION; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; IN VITRO STUDY; MYOCARDITIS; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; UPREGULATION;

ANIMALS; AUTOIMMUNE DISEASES; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; GENES, MHC CLASS II; HUMANS; IMMUNOHISTOCHEMISTRY; T-LYMPHOCYTES;

EID: 0347286787     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043453414     Document Type: Review

References (217)

1. Ignarro LJ, Byrns RE, Buga GM, Wood KS, Chaudhuri G. Pharmacological evidence that endothelium-derived relaxing factor is nitric oxide: use of pyrogallol and superoxide dismutase to study endothelium-dependent and nitric oxide-elicited vascular smooth muscle relaxation. J Pharmacol Exp Ther 1988; 244: 181-189.
2. Ignarro LJ. Nitric oxide: a unique endogenous signaling molecule in vascular biology. Biosci Rep 1999; 19: 51-71.
3. Busse R, Forstermann U, Matsuda H, Pohl U. The role of prostaglandins in the endothelium-mediated vasodilatory response to hypoxia. Pflugers Arch 1984; 401: 77-83.
4. Preissner KT. Hemostatic protease receptors and endothelial cell function: insights from gene targeting in mice. Semin Thromb Hemost 2000; 26: 451-462.
5. Pober JS. Immunobiology of human vascular endothelium. Immunol Res 1999; 19: 225-232.
6. Mantovani A, Garlanda C, Introna M, Vecchi A. Regulation of endothelial cell function by pro- and anti-inflammatory cytokines. Transplant Proc 1998; 30: 4239-4243.
7. Pober JS. Warner-Lambert/Parke-Davis award lecture. Cytokine-mediated activation of vascular endothelium. Physiology and pathology. Am J Pathol 1988; 133: 426-433.
8. Adams DH, Shaw S. Leucocyte-endothelial interactions and regulation of leucocyte migration. Lancet 1994; 343: 831-836.
9. Coll-Vinent B, Cebrian M, Cid MC, Font C, Esparza J, Juan M, et al. Dynamic pattern of endothelial cell adhesion molecule expression in muscle and perineural vessels from patients with classic polyarteritis nodosa. Arthritis Rheum 1998; 41: 435-444.
10. Verschueren PC, Voskuyl AE, Smeets TJ, Zwinderman KH, Breedveld FC, Tak PP. Increased cellularity and expression of adhesion molecules in muscle biopsy specimens from patients with rheumatoid arthritis with clinical suspicion of vasculitis, but negative routine histology. Ann Rheum Dis 2000; 59: 598-606.
11. Blann AD, Herrick A, Jayson MI. Altered levels of soluble adhesion molecules in rheumatoid arthritis, vasculitis and systemic sclerosis. Br J Rheumatol 1995; 34: 814-819.
12. Denton CP, Bickerstaff MC, Shiwen X, Carulli MT, Haskard DO, Dubois RM, et al. Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br J Rheumatol 1995; 34: 1048-1054.
13. Cush JJ, Rothlein R, Lindsley HB, Mainolfi EA, Lipsky PE. Increased levels of circulating intercellular adhesion molecule 1 in the sera of patients with rheumatoid arthritis. Arthritis Rheum 1993; 36: 1098-1102.
14. Aoki S, Imai K, Yachi A. Soluble intercellular adhesion molecule-1 (ICAM-1) antigen in patients with rheumatoid arthritis. Scand J Immunol 1993; 38: 485-490.
15. Voskuyl AE, Martin S, Melchers L, Zwinderman AH, Weichselbraun I, Breedveld FC. Levels of circulating intercellular adhesion molecule-1 and -3 but not circulating endothelial leucocyte adhesion molecule are increased in patients with rheumatoid vasculitis. Br J Rheumatol 1995; 34: 311-315.
16. Turesson C, Englund P, Jacobsson LT, Sturfelt G, Truedsson L, Nennesmo I, et al. Increased endothelial expression of HLA-DQ and interleukin 1alpha in extra-articular rheumatoid arthritis. Results from immunohistochemical studies of skeletal muscle. Rheumatology (Oxford) 2001; 40: 1346-1354.
17. Pigott R, Dillon LP, Hemingway IH, Gearing AJ. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun 1992; 187: 584-589.
18. Rothlein R, Mainolfi EA, Czajkowski M, Marlin SD. A form of circulating ICAM-1 in human serum. J Immunol 1991; 147: 3788-3793.
19. Rose ML, Coles MI, Griffin RJ, Pomerance A, Yacoub MH. Expression of class I and class II major histocompatibility antigens in normal and transplanted human heart. Transplantation 1986; 41: 776-780.
20. Fuggle SV, McWhinnie DL, Chapman JR, Taylor HM, Morris PJ. Sequential analysis of HLA-class II antigen expression in human renal allografts. Induction of tubular class II antigens and correlation with clinical parameters. Transplantation 1986; 42: 144-150.
21. Steinhoff G, Wonigeit K, Pichlmayr R. Analysis of sequential changes in major histocompatibility complex expression in human liver grafts after transplantation. Transplantation 1988; 45: 394-401.
22. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
23. Cristea A, Rus H, Niculescu F, Bedeleanu D, Vlaicu R. Characterization of circulating immune complexes in heart disease. Immunol Lett 1986; 13: 45-49.
24. Liuzzo G, Kopecky SL, Frye RL, O'Fallon WM, Maseri A, Goronzy JJ, et al. Perturbation of the T-cell repertoire in patients with unstable angina. Circulation 1999; 100: 2135-2139.
25. Mustafa A, Nityanand S, Berglund L, Lithell H, Lefvert AK. Circulating immune complexes in 50-year-old men as a strong and independent risk factor for myocardial infarction. Circulation 2000; 102: 2576-2581.
26. Hingorani AD, Cross J, Kharbanda RK, Mullen MJ, Bhagat K, Taylor M, et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation 2000; 102: 994-999.
27. Fichtlscherer S, Zeiher AM. Endothelial dysfunction in acute coronary syndromes: association with elevated C-reactive protein levels. Ann Med 2000; 32: 515-518.
28. Dhillon R, Clarkson P, Donald AE, Powe AJ, Nash M, Novelli V, et al. Endothelial dysfunction late after Kawasaki disease. Circulation 1996; 94: 2103-2106.
29. Filer AD, Gardner-Medwin JM, Thambyrajah J, Raza K, Carruthers DM, Stevens RJ, et al. Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polyarteritis nodosa. Ann Rheum Dis 2003; 62: 162-167.
30. Jacobsson LT, Turesson C, Hanson RL, Pillemer S, Sievers ML, Pettitt DJ, et al. Joint swelling as a predictor of death from cardiovascular disease in a population study of Pima Indians. Arthritis Rheum 2001; 44: 1170-1176.
31. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J, Vidan J, et al. HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med 2003; 114: 647-652.
32. Englund P, Lindroos E, Nennesmo I, Klareskog L, Lundberg IE. Skeletal muscle fibers express major histocompatibility complex class II antigens independently of inflammatory infiltrates in inflammatory myopathies. Am J Pathol 2001; 159: 1263-1273.
33. Pober JS, Gimbrone MA Jr, Cotran RS, Reiss CS, Burakoff SJ, Fiers W, et al. Ia expression by vascular endothelium is inducible by activated T cells and by human gamma interferon. J Exp Med 1983; 157: 1339-1353.
34. Collins T, Korman AJ, Wake CT, Boss JM, Kappes DJ, Fiers W, et al. Immune interferon activates multiple class II major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts. Proc Natl Acad Sci USA 1984; 81: 4917-4921.
35. Groenewegen G, Buurman WA, van der Linden CJ. Lymphokine dependence of in vivo expression of MHC class II antigens by endothelium. Nature 1985; 316: 361-363.
36. Hasegawa S, Becker G, Nagano H, Libby P, Mitchell RN. Pattern of graft- and host-specific MHC class II expression in long-term murine cardiac allografts: origin of inflammatory and vascular wall cells. Am J Pathol 1998; 153(1): 69-79.
37. Brown JH, Jardetzky T, Saper MA, Samraoui B, Bjorkman PJ, Wiley DC. A hypothetical model of the foreign antigen binding site of class II histocompatibility molecules. Nature 1988; 332: 845-850.
38. Pober JS, Orosz CG, Rose ML, Savage CO. Can graft endothelial cells initiate a host anti-graft immune response? Transplantation 1996; 61: 343-349.
39. Labarrere CA, Nelson DR, Faulk WP. Endothelial activation and development of coronary artery disease in transplanted human hearts. JAMA 1997; 278: 1169-1175.
40. Kuffova L, Holan V, Lumsden L, Forrester JV, Filipec M. Cell subpopulations in failed human corneal grafts. Br J Ophthalmol 1999; 83: 1364-1369.
41. Muczynski KA, Cotner T, Anderson SK. Unusual expression of human lymphocyte antigen class II in normal renal microvascular endothelium. Kidney Int 2001; 59: 488-497.
42. Vallbracht KB, Schwimmbeck PL, Seeberg B, Kuhl U, Schultheiss HP. Endothelial dysfunction of peripheral arteries in patients with immunohistologically confirmed myocardial inflammation correlates with endothelial expression of human leukocyte antigens and adhesion molecules in myocardial biopsies. J Am Coll Cardiol 2002; 40: 515-520.
43. Klareskog L, Johnell O, Hulth A. Expression of HLA-DR and HLA-DQ antigens on cells within the cartilage-pannus junction in rheumatoid arthritis. Rheumatol Int 1984; 4 Suppl: 11-15.
44. Barkley D, Allard S, Feldmann M, Maini RN. Increased expression of HLA-DQ antigens by interstitial cells and endothelium in the synovial membrane of rheumatoid arthritis patients compared with reactive arthritis patients. Arthritis Rheum 1989; 32: 955-963.
45. Bywaters EGL, Scott JT. The natural history of vascular lesions in rheumatoid arthritis. J Chron Dis 1963; 16: 905-914.
46. Scott DG, Bacon PA, Tribe CR. Systemic rheumatoid vasculitis: a clinical and laboratory study of 50 cases. Medicine (Baltimore) 1981; 60: 288-297.
47. Butman S, Espinoza LR, Del Carpio J, Osterland CK. Rheumatoid pericarditis. Rapid deterioration with evidence of local vasculitis. JAMA 1977; 238: 2394-2396.
48. Vaugn DG, Asbury T, Riordan-Eva P. General ophthalmology. 13 ed. Norwalk, CT: Appleton&Lange, 1992.
49. Sokoloff L, McCluksey RT, Bunim JJ. Vascularity of the early subcutaneous nodule of rheumatoid arthritis. Arch Path 1953; 55: 475-495.
50. Turesson C, Jacobsson L, Bergstrom U, Truedsson L, Sturfelt G. Predictors of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol 2000; 29(6): 358-364.
51. Bacon PA, Kitas GD. The significance of vascular inflammation in rheumatoid arthritis. Ann Rheum Dis 1994; 53: 621-623.
52. Kulka JP, Brocking D RM, Bauer W. Early joint lesions of rheumatoid arthritis: report of eight cases, with knee biopsies of lesions with less than one year's duration. Arch Path 1955; 59: 129-150.
53. Turesson C, Jacobsson L, Bergstrom U. Extra-articular rheumatoid arthritis: prevalence and mortality. Rheumatology (Oxford) 1999; 38(7): 668-674.
54. McEntegart A, Capell HA, Creran D, Rumley A, Woodward M, Lowe GD. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford) 2001; 40: 640-644.
55. del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44: 2737-2745.
56. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 1303-1307.
57. Jacobsson LT, Knowler WC, Pillemer S, Hanson RL, Pettitt DJ, Nelson RG, et al. Rheumatoid arthritis and mortality. A longitudinal study in Pima Indians. Arthritis Rheum 1993; 36: 1045-1053.
58. Myllykangas-Luosujarvi R, Aho K, Kautiainen H, Isomaki H. Cardiovascular mortality in women with rheumatoid arthritis. J Rheumatol 1995; 22: 1065-1067.
59. Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 1997; 24: 445-451.
60. Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol 1999; 26: 2562-2571.
61. Wislowska M, Sypula S, Kowalik I. Echocardiographic findings and 24-h electrocardiographic Holter monitoring in patients with nodular and non-nodular rheumatoid arthritis. Rheumatol Int 1999; 18: 163-169.
62. Gordon DA, Stein JL, Broder I. The extra-articular features of rheumatoid arthritis. A systematic analysis of 127 cases. Am J Med 1973; 54: 445-452.
63. Foster CS, Forstot SL, Wilson LA. Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression. Ophthalmology 1984; 91: 1253-1263.
64. Erhardt CC, Mumford PA, Venables PJ, Maini RN. Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study. Ann Rheum Dis 1989; 48: 7-13.
65. Hara KS, Ballard DJ, Ilstrup DM, Connolly DC, Vollertsen RS. Rheumatoid pericarditis: clinical features and survival. Medicine (Baltimore) 1990; 69: 81-91.
66. Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol 2002; 29: 62-67.
67. Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 2002; 46: 862-873.
68. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976; 60: 221-225.
69. Aranow C, Ginzler EM. Epidemiology of cardiovascular disease in systemic lupus erythematosus. Lupus 2000; 9: 166-169.
70. Cheah PL, Looi LM, Chua CT, Yap SF, Fleming S. Enhanced major histocompatibility complex (MHC) class II antigen expression in lupus nephritis. Malays J Pathol 1997; 19: 115-120.
71. van der MK, Hinojoza JR, Sobel RA. Endothelial cell class II major histocompatibility complex molecule expression in stereotactic brain biopsies of patients with acute inflammatory/demyelinating conditions. J Neuropathol Exp Neurol 1999; 58: 346-358.
72. Yokoyama K, Mitomi H, Kobayashi K, Katsumata T, Saigenji K, Okayasu I. Obliterative arteritis with nitric oxide synthase and HLA-DR expression in Crohn's colitis. Hepatogastroenterology 2001; 48: 401-407.
73. Lundberg IE, Dastmalchi M. Possible pathogenic mechanisms in inflammatory myopathies. Rheum Dis Clin North Am 2002; 28: 799-822.
74. De Letter MA, van Doorn PA, Savelkoul HF, Laman JD, Schmitz PI, Op de Coul AA, et al. Critical illness polyneuropathy and myopathy (CIPNM): evidence for local immune activation by cytokine-expression in the muscle tissue. J Neuroimmunol 2000; 106: 206-213.
75. Herskowitz A, Ahmed-Ansari A, Neumann DA, Beschorner WE, Rose NR, Soule LM, et al. Induction of major histocompatibility complex antigens within the myocardium of patients with active myocarditis: a nonhistologic marker of myocarditis. J Am Coll Cardiol 1990; 15: 624-632.
76. Caforio AL, Stewart JT, Bonifacio E, Burke M, Davies MJ, McKenna WJ, et al. Inappropriate major histocompatibility complex expression on cardiac tissue in dilated cardiomyopathy. Relevance for autoimmunity? J Autoimmun 1990; 3: 187-200.
77. Caforio AL, Mahon NJ, Tona F, McKenna WJ. Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance. Eur J Heart Fail 2002; 4: 411-417.
78. Michels VV, Moll PP, Miller FA, Tajik AJ, Chu JS, Driscoll DJ, et al. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med 1992; 326: 77-82.
79. Baig MK, Goldman JH, Caforio AL, Coonar AS, Keeling PJ, McKenna WJ. Familial dilated cardiomyopathy: cardiac abnormalities are common in asymptomatic relatives and may represent early disease. J Am Coll Cardiol 1998; 31: 195-201.
80. Caforio AL. Role of autoimmunity in dilated cardiomyopathy. Br Heart J 1994; 72: S30-S34.
81. Caforio AL, Goldman JH, Haven AJ, Baig KM, McKenna WJ. Evidence for autoimmunity to myosin and other heart-specific autoantigens in patients with dilated cardiomyopathy and their relatives. Int J Cardiol 1996; 54: 157-163.
82. Sigusch HH, Lehmann MH, Schnittler U, Reinhardt D, Figulla HR. Tumour necrosis factor-alpha expression in idiopathic dilated cardiomyopathy: correlation to myocardial inflammatory activity. Cytokine 2000; 12: 1261-1266.
83. Mahon NG, Madden BP, Caforio AL, Elliott PM, Haven AJ, Keogh BE, et al. Immunohistologic evidence of myocardial disease in apparently healthy relatives of patients with dilated cardiomyopathy. J Am Coll Cardiol 2002; 39: 455-462.
84. Noutsias M, Pauschinger M, Kuhl U, Schultheiss HP. Immunosuppressive treatment in familial dilated cardiomyopathy with biopsy-proven intramyocardial inflammation? J Am Coll Cardiol 2003; 41: 169-170.
85. Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation 1991; 84: 1589-1596.
86. Drexler H, Hayoz D, Munzel T, Hornig B, Just H, Brunner HR, et al. Endothelial function in chronic congestive heart failure. Am J Cardiol 1992; 69: 1596-1601.
87. Potts WK, Slev PR. Pathogen-based models favoring MHC genetic diversity. Immunol Rev 1995; 143:181-97.
88. Jensen PE, Weber DA, Thayer WP, Chen X, Dao CT. HLA-DM and the MHC class II antigen presentation pathway. Immunol Res 1999; 20: 195-205.
89. Denzin LK, Sant'Angelo DB, Hammond C, Surman MJ, Cresswell P. Negative regulation by HLA-DO of MHC class II-restricted antigen processing. Science 1997; 278: 106-109.
90. Beck S, Trowsdale J. Sequence organisation of the class II region of the human MHC. Immunol Rev 1999; 167: 201-10.
91. McDevitt HO. Discovering the role of the major histocompatibility complex in the immune response. Annu Rev Immunol 2000; 18: 1-17.
92. Wicker LS. Major histocompatibility complex-linked control of autoimmunity. J Exp Med 1997; 186: 973-975.
93. Baisch JM, Weeks T, Giles R, Hoover M, Stastny P, Capra JD. Analysis of HLA-DQ genotypes and susceptibility in insulin-dependent diabetes mellitus. N Engl J Med 1990; 322: 1836-1841.
94. de Moerloose P, Jeannet M, Martins-da-Silva B, Werner-Favre C, Rohr J, Gauthier G. Increased frequency of HLA - DRw2 and DRw3 in multiple sclerosis. Tissue Antigens 1979; 13: 357-360.
95. So AK, Fielder AH, Warner CA, Isenberg DA, Batchelor JR, Walport MJ. DNA polymorphism of major histocompatibility complex class II and class III genes in systemic lupus erythematosus. Tissue Antigens 1990; 35: 144-147.
96. Naeim F, Keesey JC, Herrmann C Jr, Lindstrom J, Zeller E, Walford RL. Association of HLA-B8, DRw3, and anti-acetylcholine receptor antibodies in myasthenia gravis. Tissue Antigens 1978; 12: 381-386.
97. Weissel M, Hofer R, Zasmeta H, Mayr WR. HLA-DR and Hashimoto's thyroiditis. Tissue Antigens 1980; 16: 256-257.
98. Stastny P. Mixed lymphocyte cultures in rheumatoid arthritis. J Clin Invest 1976; 57: 1148-1157.
99. Gibofsky A, Winchester R, Hansen J, Patarroyo M, Dupont B, Paget S, et al. Contrasting patterns of newer histocompatibility determinants in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum 1978; 21: S134-S138.
100. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30: 1205-1213.
101. Williams RC, Jacobsson LT, Knowler WC, del Puente A, Kostyu D, McAuley JE, et al. Meta-analysis reveals association between most common class II haplotype in full-heritage Native Americans and rheumatoid arthritis. Hum Immunol 1995; 42: 90-94.
102. Beasley RP, Willkens RF, Bennett PH. High prevalence of rheumatoid arthritis in Yakima Indians. Arthritis Rheum 1973; 16: 743-748.
103. del Puente A, Knowler WC, Pettitt DJ, Bennett PH. High incidence and prevalence of rheumatoid arthritis in Pima Indians. Am J Epidemiol 1989; 129: 1170-1178.
104. Deighton CM, Walker DJ, Griffiths ID, Roberts DF. The contribution of HLA to rheumatoid arthritis. Clin Genet 1989; 36: 178-182.
105. Cornelis F, Faure S, Martinez M, Prud'homme JF, Fritz P, Dib C, et al. New susceptibility locus for rheumatoid arthritis suggested by a genome-wide linkage study. Proc Natl Acad Sci USA 1998; 95(18): 10746-10750.
106. Jawaheer D, Seldin MF, Amos CI, Chen WV, Shigeta R, Monteiro J, et al. A genomewide screen in multiplex rheumatoid arthritis families suggests genetic overlap with other autoimmune diseases. Am J Hum Genet 2001; 68: 927-936.
107. Jawaheer D, Seldin MF, Amos CI, Chen WV, Shigeta R, Etzel C, et al. Screening the genome for rheumatoid arthritis susceptibility genes: a replication study and combined analysis of 512 multicase families. Arthritis Rheum 2003; 48: 906-916.
108. Shiozawa S, Hayashi S, Tsukamoto Y, Goko H, Kawasaki H, Wada T, et al. Identification of the gene loci that predispose to rheumatoid arthritis. Int Immunol 1998; 10: 1891-1895.
109. Weyand CM, Hicok KC, Conn DL, Goronzy JJ. The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann Intern Med 1992; 117: 801-806.
110. Gough A, Faint J, Salmon M, Hassell A, Wordsworth P, Pilling D, et al. Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome. Arthritis Rheum 1994; 37: 1166-1170.
111. Wagner U, Kaltenhauser S, Sauer H, Arnold S, Seidel W, Hantzschel H, et al. HLA markers and prediction of clinical course and outcome in rheumatoid arthritis. Arthritis Rheum 1997; 40: 341-351.
112. Hillarby MC, Clarkson R, Grennan DM, Bate AS, Ollier W, Sanders PA, et al. Immunogenetic heterogeneity in rheumatoid disease as illustrated by different MHC associations (DQ, Dw and C4) in articular and extra-articular subsets. Br J Rheumatol 1991; 30: 5-9.
113. Weyand CM, Xie C, Goronzy JJ. Homozygosity for the HLA-DRB1 allele selects for extraarticular manifestations in rheumatoid arthritis. J Clin Invest 1992; 89: 2033-2039.
114. Perdriger A, Chales G, Semana G, Guggenbuhl P, Meyer O, Quillivic F, et al. Role of HLA-DR-DR and DR-DQ associations in the expression of extraarticular manifestations and rheumatoid factor in rheumatoid arthritis. J Rheumatol 1997; 24: 1272-1276.
115. Klareskog L, Forsum U, Scheynius A, Kabelitz D, Wigzell H. Evidence in support of a self-perpetuating HLA-DR-dependent delayed-type cell reaction in rheumatoid arthritis. Proc Natl Acad Sci USA 1982; 79: 3632-3636.
116. Todd JA, Acha-Orbea H, Bell JI, Chao N, Fronek Z, Jacob CO, et al. A molecular basis for MHC class II - associated autoimmunity. Science 1988; 240:1003-1009.
117. Roudier J, Petersen J, Rhodes GH, Luka J, Carson DA. Susceptibility to rheumatoid arthritis maps to a T-cell epitope shared by the HLA-Dw4 DR beta-1 chain and the Epstein-Barr virus glycoprotein gp110. Proc Natl Acad Sci USA 1989; 86: 5104-5108.
118. Albani S, Tuckwell JE, Esparza L, Carson DA, Roudier J. The susceptibility sequence to rheumatoid arthritis is a cross-reactive B cell epitope shared by the Escherichia coli heat shock protein dnaJ and the histocompatibility leukocyte antigen DRB10401 molecule. J Clin Invest 1992; 89: 327-331.
119. Weyand CM, Goronzy JJ. Functional domains on HLA-DR molecules: implications for the linkage of HLA-DR genes to different autoimmune diseases. Clin Immunol Immunopathol 1994; 70: 91-98.
120. Walser-Kuntz DR, Weyand CM, Weaver AJ, O'Fallon WM, Goronzy JJ. Mechanisms underlying the formation of the T cell receptor repertoire in rheumatoid arthritis. Immunity 1995; 2: 597-605.
121. Nanki T, Kohsaka H, Mizushima N, Ollier WE, Carson DA, Miyasaka N. Genetic control of T cell receptor BJ gene expression in peripheral lymphocytes of normal and rheumatoid arthritis monozygotic twins. J Clin Invest 1996; 98:1594-1601.
122. Berg LJ, Frank GD, Davis MM. The effects of MHC gene dosage and allelic variation on T cell receptor selection. Cell 1990; 60: 1043-1053.
123. Hirayama K, Matsushita S, Kikuchi I, Iuchi M, Ohta N, Sasazuki T. HLA-DQ is epistatic to HLA-DR in controlling the immune response to schistosomal antigen in humans. Nature 1987; 327: 426-430.
124. Altmann DM, Sansom D, Marsh SG. What is the basis for HLA-DQ associations with autoimmune disease? Immunol Today 1991; 12: 267-270.
125. Zanelli E, Huizinga TW, Guerne PA, Vischer TL, Tiercy JM, Verduyn W, et al. An extended HLA-DQ-DR haplotype rather than DRB1 alone contributes to RA predisposition. Immunogenetics 1998; 48: 394-401.
126. van der Horst-Bruinsma IE, Visser H, Hazes JM, Breedveld FC, Verduyn W, Schreuder GM, et al. HLA-DQ-associated predisposition to and dominant HLA-DR-associated protection against rheumatoid arthritis. Hum Immunol 1999; 60: 152-158.
127. de Vries N, van Elderen C, Tijssen H, van Riel PL, van de Putte LB. No support for HLA-DQ encoded susceptibility in rheumatoid arthritis. Arthritis Rheum 1999; 42: 1621-1627.
128. Lanchbury JS, Jaeger EE, Sansom DM, Hall MA, Wordsworth P, Stedeford J, et al. Strong primary selection for the Dw4 subtype of DR4 accounts for the HLA-DQw7 association with Felty's syndrome. Hum Immunol 1991; 32: 56-64.
129. Coakley G, Brooks D, Iqbal M, Kondeatis E, Vaughan R, Loughran TP Jr, et al. Major histocompatility complex haplotypic associations in Felty's syndrome and large granular lymphocyte syndrome are secondary to allelic association with HLA-DRB1 *0401. Rheumatology (Oxford) 2000; 39: 393-398.
130. Newton J, Brown MA, Milicic A, Ackerman H, Darke C, Wilson JN, et al. The effect of HLA-DR on susceptibility to rheumatoid arthritis is influenced by the associated lymphotoxin alpha-tumor necrosis factor haplotype. Arthritis Rheum 2003; 48: 90-96.
131. Schur PH, Marcus-Bagley D, Awdeh Z, Yunis EJ, Alper CA. The effect of ethnicity on major histocompatibility complex complement allotypes and extended haplotypes in patients with systemic lupus erythematosus. Arthritis Rheum 1990; 33: 985-992.
132. Bettinotti MP, Hartung K, Deicher HR, Keller E, Mikschl S, Albert E. DR2 haplotypes (DRB1, DQA1, DQB1) associated with systemic lupus erythematosus. Immunogenetics 1993; 38: 74-77.
133. Reveille JD, Moulds JM, Ahn C, Friedman AW, Baethge B, Roseman J, et al. Systemic lupus erythematosus in three ethnic groups: I. The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. LUMINA Study Group. Lupus in minority populations, nature versus nurture. Arthritis Rheum 1998; 41: 1161-1172.
134. Mattey DL, Hassell AB, Dawes PT, Ollier WE, Hajeer A. Interaction between tumor necrosis factor microsatellite polymorphisms and the HLA-DRB1 shared epitope in rheumatoid arthritis: influence on disease outcome. Arthritis Rheum 1999; 42: 2698-2704.
135. Mu H, Chen JJ, Jiang Y, King MC, Thomson G, Criswell LA. Tumor necrosis factor a microsatellite polymorphism is associated with rheumatoid arthritis severity through an interaction with the HLA-DRB1 shared epitope. Arthritis Rheum 1999; 42: 438-442.
136. Mattey DL, Dawes PT, Fisher J, Brownfield A, Thomson W, Hajeer AH, et al. Nodular disease in rheumatoid arthritis: association with cigarette smoking and HLA-DRB1/TNF gene interaction. J Rheumatol 2002; 29: 2313-2318.
137. Thomas R, Davis LS, Lipsky PE. Comparative accessory cell function of human peripheral blood dendritic cells and monocytes. J Immunol 1993; 151: 6840-6852.
138. Eberl G, Roggero MA, Corradin G. A simple mathematical model for the functional peptide/MHC/TCR interactions. J Immunol 1995; 154: 219-225.
139. Boss JM. Regulation of transcription of MHC class II genes. Curr Opin Immunol 1997; 9: 107-113.
140. Rosen FS, Cooper MD, Wedgwood RJ. The primary immunodeficiencies. N Engl J Med 1995; 333: 431-440.
141. Wolf HM, Thon V, Gulle H, Lechleitner S, Eibl MM, Petzelbauer P. Residual expression of functional MHC class II molecules in twin brothers with MHC class II deficiency is cell type specific. Br J Haematol 2001; 115: 460-471.
142. Steimle V, Otten LA, Zufferey M, Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 1993; 75: 135-146.
143. Chang CH, Flavell RA. Class II transactivator regulates the expression of multiple genes involved in antigen presentation. J Exp Med 1995; 181: 765-767.
144. Steimle V, Durand B, Barras E, Zufferey M, Hadam MR, Mach B, et al. A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes Dev 1995; 9: 1021-1032.
145. Masternak K, Barras E, Zufferey M, Conrad B, Corthals G, Aebersold R, et al. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nat Genet 1998; 20: 273-277.
146. Durand B, Sperisen P, Emery P, Barras E, Zufferey M, Mach B, et al. RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency. EMBO J 1997; 16: 1045-1055.
147. Peretti M, Villard J, Barras E, Zufferey M, Reith W. Expression of the three human major histocompatibility complex class II isotypes exhibits a differential dependence on the transcription factor RFXAP. Mol Cell Biol 2001; 21: 5699-5709.
148. Beaty JS, West KA, Nepom GT. Functional effects of a natural polymorphism in the transcriptional regulatory sequence of HLA-DQB1. Mol Cell Biol 1995; 15: 4771-4782.
149. Cesari M, Caillens H, Cadet F, Pabion M. In vivo analysis of HLA-DQ gene expression in heterozygous cell lines. Immunogenetics 1999; 50: 309-318.
150. Diamantopoulos EJ, Andreadis EA, Vassilopoulos CV, Vlachonikolis IG, Tarassi KE, Chatzis NA, et al. Association of specific HLA phenotypes with left ventricular mass and carotid intima-media thickness in hypertensives. Am J Hypertens 2001; 14: 632-636.
151. Persson J, Formgren J, Israelsson B, Berglund G. Ultrasound-determined intima-media thickness and atherosclerosis. Direct and indirect validation. Arterioscler Thromb 1994; 14: 261-264.
152. Chambers J. Left ventricular hypertrophy. BMJ 1995; 311: 273-274.
153. Steimle V, Siegrist CA, Mottet A, Lisowska-Grospierre B, Mach B. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 1994; 265: 106-109.
154. Wedgwood JF, Hatam L, Bonagura VR. Effect of interferon-gamma and tumor necrosis factor on the expression of class I and class II major histocompatibility molecules by cultured human umbilical vein endothelial cells. Cell Immunol 1988; 111: 1-9.
155. Leeuwenberg JF, Van Damme J, Meager T, Jeunhomme TM, Buurman WA. Effects of tumor necrosis factor on the interferon-gamma-induced major histocompatibility complex class II antigen expression by human endothelial cells. Eur J Immunol 1988; 18: 1469-1472.
156. Roebuck KA, Rahman A, Lakshminarayanan V, Janakidevi K, Malik AB. H2O2 and tumor necrosis factor-alpha activate intercellular adhesion molecule 1 (ICAM-1) gene transcription through distinct cis-regulatory elements within the ICAM-1 promoter. J Biol Chem 1995; 270: 18966-18974.
157. Sherman PA, Basta PV, Ting JP. Upstream DNA sequences required for tissue-specific expression of the HLA-DR alpha gene. Proc Natl Acad Sci USA 1987; 84: 4254-4258.
158. Grimm M, Spiecker M, De Caterina R, Shin WS, Liao JK. Inhibition of major histocompatibility complex class II gene transcription by nitric oxide and antioxidants. J Biol Chem 2002; 277: 26460-26467.
159. Benoist C, Mathis D. Regulation of major histocompatibility complex class-II genes: X, Y and other letters of the alphabet. Annu Rev Immunol 1990; 8: 681-715.
160. Schreck R, Albermann K, Baeuerle PA. Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells (a review). Free Radic Res Commun 1992; 17(4): 221-237.
161. Srisatjaluk R, Doyle RJ, Justus DE. Outer membrane vesicles of Porphyromonas gingivalis inhibit IFN-gamma-mediated MHC class II expression by human vascular endothelial cells. Microb Pathog 1999; 27: 81-91.
162. Soilu-Hanninen M, Salmi A, Salonen R. Interferon-beta downregulates expression of VLA-4 antigen and antagonizes interferon-gamma-induced expression of HLA-DQ on human peripheral blood monocytes. J Neuroimmunol 1995; 60: 99-106.
163. Lapierre LA, Fiers W, Pober JS. Three distinct classes of regulatory cytokines control endothelial cell MHC antigen expression. Interactions with immune gamma interferon differentiate the effects of tumor necrosis factor and lymphotoxin from those of leukocyte alpha and
164. Doukas J, Pober JS. IFN-gamma enhances endothelial activation induced by tumor necrosis factor but not IL-1. J Immunol 1990; 145: 1727-1733.
165. Baum D, Yaron R, Yellin MJ. TNF-alpha, not CD154 (CD40L), plays a major role in SEB-dependent, CD4(+) T cell-induced endothelial cell activation in vitro. Cell Immunol 1998; 190: 12-22.
166. Sakito S, Ueki Y, Eguchi K, Kawabe Y, Nagataki S. Serum cytokines in patients with rheumatoid arthritis. Correlation of interferon gamma and tumor necrosis factor alpha with the characteristics of peripheral blood mononuclear cells. Rheumatol Int 1995; 15: 31-37.
167. Bakri HA, Ronnelid J, Gunnarsson I, Karlsson G, Berg L, Lundberg I. Increased serum levels of immunoglobulins, C-reactive protein, type 1 and type 2 cytokines in patients with mixed connective tissue disease. J Autoimmun 1998; 11: 503-508.
168. Hagiwara E, Gourley MF, Lee S, Klinman DK. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10:interferon-gamma-secreting cells in the peripheral blood. Arthritis Rheum 1996; 39: 379-385.
169. Robak E, Sysa-Jedrzejewska A, Dziankowska B, Torzecka D, Chojnowski K, Robak T. Association of interferon gamma, tumor necrosis factor alpha and interleukin 6 serum levels with systemic lupus erythematosus activity. Arch Immunol Ther Exp (Warsz) 1998; 46: 375-380.
170. Saxne T, Palladino MA Jr, Heinegard D, Talal N, Wollheim FA. Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988; 31: 1041-1045.
171. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14: 397-440.
172. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-1602.
173. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Eng] J Med 2000; 343: 1586-1593.
174. Kuryliszyn-Moskal A. Cytokines and soluble CD4 and CD8 molecules in rheumatoid arthritis: relationship to systematic vasculitis and microvascular capillaroscopic abnormalities. Clin Rheumatol 1998; 17: 489-495.
175. Ronnelid J, Berg L, Rogberg S, Nilsson A, Albertsson K, Klareskog L. Production of T-cell cytokines at the single-cell level in patients with inflammatory arthritides: enhanced activity in synovial fluid compared to blood. Br J Rheumatol 1998; 37: 7-14.
176. Schmidt D, Martens PB, Weyand CM, Goronzy JJ. The repertoire of CD4+ CD28- T cells in rheumatoid arthritis. Mol Med 1996; 2: 608-618.
177. Martens PB, Goronzy JJ, Schaid D, Weyand CM. Expansion of unusual CD4+ T cells in severe rheumatoid arthritis. Arthritis Rheum 1997; 40: 1106-1114.
178. Pawlik A, Ostanek L, Brzosko I, Brzosko M, Masiuk M, Machalinski B, et al. The expansion of CD4+CD28- T cells in patients with rheumatoid arthritis. Arthritis Res Ther 2003; 5: R210-R213.
179. Pober JS, Collins T, Gimbrone MA Jr, Cotran RS, Gitlin JD, Fiers W, et al. Lymphocytes recognize human vascular endothelial and dermal fibroblast Ia antigens induced by recombinant immune interferon. Nature 1983; 305: 726-729.
180. Savage CO, Hughes CC, McIntyre BW, Picard JK, Pober JS. Human CD4+ T cells proliferate to HLA-DR+ allogeneic vascular endothelium. Identification of accessory interactions. Transplantation 1993; 56: 128-134.
181. Pardi R, Bender JR. Signal requirements for the generation of CD4+ and CD8+ T-cell responses to human allogeneic microvascular endothelium. Circ Res 1991; 69: 1269-1279.
182. Marelli-Berg FM, Hargreaves RE, Carmichael P, Dorling A, Lombardi G, Lechler RI. Major histocompatibility complex class II-expressing endothelial cells induce allospecific nonresponsiveness in naive T cells. J Exp Med 1996; 183: 1603-1612.
183. Prat A, Biernacki K, Becher B, Antel JP. B7 expression and antigen presentation by human brain endothelial cells: requirement for proinflammatory cytokines. J Neuropathol Exp Neurol 2000; 59: 129-136.
184. Marelli-Berg FM, Frasca L, Weng L, Lombardi G, Lechler RI. Antigen recognition influences transendothelial migration of CD4+ T cells. J Immunol 1999; 162: 696-703.
185. Greening JE, Tree TI, Kotowicz KT, van Halteren AG, Roep BO, Klein NJ, et al. Processing and presentation of the islet autoantigen GAD by vascular endothelial cells promotes transmigration of autoreactive T-cells. Diabetes 2003; 52: 717-725.
186. Haynes BF, Grover BJ, Whichard LP, Hale LP, Nunley JA, McCollum DE, et al. Synovial microenvironment-T cell interactions. Human T cells bind to fibroblast-like synovial cells in vitro. Arthritis Rheum 1988; 31: 947-955.
187. Vallejo AN, Mugge LO, Klimiuk PA, Weyand CM, Goronzy JJ. Central role of thrombospondin-1 in the activation and clonal expansion of inflammatory T cells. J Immunol 2000; 164: 2947-2954.
188. Koch AE, Friedman J, Burrows JC, Haines GK, Bouck NP. Localization of the angiogenesis inhibitor thrombospondin in human synovial tissues. Pathobiology 1993; 61: 1-6.
189. Hughes CC, Savage CO, Pober JS. Endothelial cells augment T cell interleukin 2 production by a contact-dependent mechanism involving CD2/LFA-3 interaction. J Exp Med 1990; 171: 1453-1467.
190. Savage CO, Hughes CC, Pepinsky RB, Wallner BP, Freedman AS, Pober JS. Endothelial cell lymphocyte function-associated antigen-3 and an unidentified ligand act in concert to provide costimulation to human peripheral blood CD4+ T cells. Cell Immunol 1991; 137: 150-163.
191. Sultan P, Schechner JS, McNiff JM, Hochman PS, Hughes CC, Lorber MI, et al. Blockade of CD2-LFA-3 interactions protects human skin allografts in immunodeficient mouse/human chimeras. Nat Biotechnol 1997; 15: 759-762.
192. Moosig F, Csernok E, Wang G, Gross WL. Costimulatory molecules in Wegener's granulomatosis (WG): lack of expression of CD28 and preferential up-regulation of its ligands B7-1 (CD80) and B7-2 (CD86) on T cells. Clin Exp Immunol 1998; 114: 113-118.
193. Park W, Weyand CM, Schmidt D, Goronzy JJ. Co-stimulatory pathways controlling activation and peripheral tolerance of human CD4+CD28- T cells. Eur J Immunol 1997; 27: 1082-1090.
194. Namekawa T, Snyder MR, Yen JH, Goehring BE, Leibson PJ, Weyand CM, et al. Killer cell activating receptors function as costimulatory molecules on CD4+CD28null T cells clonally expanded in rheumatoid arthritis. J Immunol 2000; 165: 1138-1145.
195. Warrington KJ, Takemura S, Goronzy JJ, Weyand CM. CD4+, CD28- T cells in rheumatoid arthritis patients combine features of the innate and adaptive immune systems. Arthritis Rheum 2001; 44: 13-20.
196. Yen JH, Moore BE, Nakajima T, Scholl D, Schaid DJ, Weyand CM, et al. Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. J Exp Med 2001; 193: 1159-1167.
197. Liuzzo G, Goronzy JJ, Yang H, Kopecky SL, Holmes DR, Frye RL, et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 2000; 101: 2883-2888.
198. Nakajima T, Schulte S, Warrington KJ, Kopecky SL, Frye RL, Goronzy JJ, et al. T-cell-mediated lysis of endothelial cells in acute coronary syndromes. Circulation 2002; 105: 570-575.
199. Colonna M, Samaridis J. Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science 1995; 268: 405-408.
200. Snyder DS, Unanue ER. Corticosteroids inhibit murine macrophage Ia expression and interleukin 1 production. J Immunol 1982; 129: 1803-1805.
201. Bunjes D, Hardt C, Rollinghoff M, Wagner H. Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2. Eur J Immunol 1981; 11: 657-661.
202. Reem GH, Cook LA, Vilcek J. Gamma interferon synthesis by human thymocytes and T lymphocytes inhibited by cyclosporin A. Science 1983; 221: 63-65.
203. Groenewegen G, Buurman WA, Jeunhomme GM, van der Linden CJ. Effect of cyclosporine on MHC class II antigen expression on arterial and venous endothelium in vitro. Transplantation 1985; 40: 21-25.
204. Chen W, Thoburn CJ, Miura Y, Sommer M, Hruban R, Qian Z, et al. Autoimmune-mediated vasculopathy. Clin Immunol 2001; 100: 57-70.
205. Taylor PC. Anti-TNFalpha therapy for rheumatoid arthritis: an update. Intern Med 2003; 42: 15-20.
206. Paleolog EM, Hunt M, Elliott MJ, Feldmann M, Maini RN, Woody JN. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum 1996; 39: 1082-1091.
207. Taylor PC, Peters AM, Paleolog E, Chapman PT, Elliott MJ, McCloskey R, et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum 2000; 43: 38-47.
208. den Broeder AA, van den Hoogen FH, van de Putte LB. Isolated digital vasculitis in a patient with rheumatoid arthritis: good response to tumour necrosis factor alpha blocking treatment. Ann Rheum Dis 2001; 60: 538-539.
209. Unger L, Kayser M, Nusslein HG. Successful treatment of severe rheumatoid vasculitis by infliximab. Ann Rheum Dis 2003; 62: 587-588.
210. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
211. Bellosta S, Via D, Canavesi M, Pfister P, Fumagalli R, Paoletti R, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998; 18: 1671-1678.
212. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001;103: 926-933.
213. Kwak B, Mulhaupt F, Veillard N, Pelli G, Mach F. The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Swiss Med Wkly 2001; 131: 41-46.
214. Sadeghi MM, Tiglio A, Sadigh K, O'Donnell L, Collinge M, Pardi R, et al. Inhibition of interferon-gamma-mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors. Transplantation 2001; 71: 1262-1268.
215. Friedman EJ. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Design 2002; 8(19): 1765-80.
216. Gomariz RP, Martinez C, Abad C, Leceta J, Delgado M. Immunology of VIP: a review and therapeutical perspectives. Curr Pharm Design 2001; 7(2): 89-111.
217. Wan Y, Bramson J. Role of dendritic cell-derived cytokines in immune regulation. Curr Pharm Design 2001; 7(11): 977-92.